Technavio has announced its latest pipeline analysis report on the rabies market. The report includes a detailed analysis of the pipeline molecules under investigation within the defined data collection period to treat chondrosarcoma.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180622005663/en/
This report by Technavio presents a detailed analysis of the market, including regulatory framework, drug development strategies, recruitment strategies, and key companies that are expected to play an essential role in the growth of the market in the coming years.
This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing
Rabies: Market overview
Rabies is a viral disease that causes acute irritation of the brain in humans and other animals. Rabies is spread to humans from animals such as dogs, cats, and cows. Rabies can be spread when an infected animal scratches or bites humans. The saliva from an infected animal can also spread rabies if it comes in contact with a human body part. Some of the symptoms of rabies include incubation, prodrome, acute neurologic pain, and coma.
According to a senior analyst at Technavio for infectious and rare diseases, “According to a major research, the cases of human rabies in the US is very rare. There are only one to three cases reported annually for human rabies. There were only 8 cases of human rabies that were reported in the US in the last 10 years. Dog rabies vaccination programs have stopped the natural spread of rabies among domestic dogs.”
Rabies: Segmentation analysis
This market research report segments the rabies market based on therapies employed (monotherapy, combination and unknown), RoA (intradermal, intradermal/intramuscular, intramuscular, and unknown), therapeutic modality (monoclonal antibody, small molecule, vaccine, and unknown), targets (innate immune cells, immune system, immunoglobin, rabies glycoprotein, and unknown), MoA (innate immune cell activator, immunostimulant, immunoglobulin replacement, rabies glycoprotein encoder, unknown, and immunoglobulin activator), and recruitment status (completed, active not recruiting, and unknown).
Monotherapy includes the use of a single drug to treat a disorder or a disease. In the current pipeline, around 42.86% of the molecules that are being investigated for the treatment of rabies are monotherapy.
In case of intradermal RoA, the drugs are applied within the layers of the skin. About 4.77% of the total therapeutics are being developed for intradermal RoA.
Looking for more information on this market? Request a free sample report
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Some of the key topics covered in the report include:
Scope of the Report
Drug Development Landscape
- Drugs under development
- Indications coverage
Drug Development Strategies
- Therapies employed
- Therapeutic modality
- Geographical coverage
- Recruitment status
- Recruitment volume
- Type of players
- Company Overview
Discontinued or Dormant Molecules
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at email@example.com.